--- title: "JINYU and others established a supply chain company in Zhejiang" type: "News" locale: "en" url: "https://longbridge.com/en/news/251115812.md" description: "According to the Qichacha APP, recently, Zhejiang Jinyu Baoling Supply Chain Co., Ltd. was established with a registered capital of 10 million yuan. Its business scope includes: supply chain management services; Internet of Things application services; research and development of biological feed, etc. Qichacha's equity penetration shows that the company is jointly held by JINYU's wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. and others" datetime: "2025-08-01T05:27:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/251115812.md) - [en](https://longbridge.com/en/news/251115812.md) - [zh-HK](https://longbridge.com/zh-HK/news/251115812.md) --- # JINYU and others established a supply chain company in Zhejiang According to the Qichacha APP, recently, Zhejiang Jinyu Baoling Supply Chain Co., Ltd. was established with a registered capital of 10 million yuan. Its business scope includes: supply chain management services; Internet of Things application services; research and development of biological feed, etc. Qichacha's equity penetration shows that the company is jointly held by JINYU's wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. and others ### Related Stocks - [600201.CN](https://longbridge.com/en/quote/600201.CN.md) ## Related News & Research - [06:06 ETWildlife experts offer seasonal tips to help orphaned or injured baby animals](https://longbridge.com/en/news/287197533.md) - [ZAWYA: Kia’s global partner, The Ocean Cleanup expands plastic interception project ahead of LA28](https://longbridge.com/en/news/287182378.md) - [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md) - [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md) - [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)